Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 2Not yet recruiting 1Enrolling by invitation 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Breast Neoplasms 80Neoplasms 61Colorectal Neoplasms 42Prostatic Neoplasms 41Carcinoma, Non-Small-Cell Lung 35Lung Neoplasms 31Multiple Myeloma 23Leukemia, Myeloid, Acute 23Head and Neck Neoplasms 22Pancreatic Neoplasms 15Melanoma 15Squamous Cell Carcinoma of Head and Neck 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Ovarian Neoplasms 14Neoplasm Metastasis 14Carcinoma, Hepatocellular 14Recurrence 13Lymphoma, Non-Hodgkin 13Stomach Neoplasms 12Colonic Neoplasms 11Uterine Cervical Neoplasms 10Rectal Neoplasms 10Lymphoma 10Esophageal Neoplasms 10Carcinoma, Renal Cell 10Brain Neoplasms 10Motor Activity 9Kidney Neoplasms 9Myelodysplastic Syndromes 8Lymphoma, Large B-Cell, Diffuse 8

Interventions

siltuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Cytokine Release Syndrome × 30 days × Clear all
NCT04975555 2026-06-03

Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy

University of Alabama at Birmingham

Phase 2 Completed
24 enrolled 8 charts
LymphoidOther hematologic neoplasmPlasma cell

Cytokine Release Syndrome, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡